Flumazenil Reversal of Oral Triazolam
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date ICMJE | June 9, 2008 | ||||
Last Updated Date | June 11, 2008 | ||||
Start Date ICMJE | September 2006 | ||||
Primary Completion Date | December 2007 (final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Observer Assessment of Alertness/Sedation [ Time Frame: 360 minutes ] [ Designated as safety issue: Yes ] | ||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | Complete list of historical versions of study NCT00695630 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures ICMJE |
BIS [ Time Frame: 360 minutes ] [ Designated as safety issue: Yes ] | ||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||
Current Other Outcome Measures ICMJE | |||||
Original Other Outcome Measures ICMJE | |||||
Descriptive Information | |||||
Brief Title ICMJE | Flumazenil Reversal of Oral Triazolam | ||||
Official Title ICMJE | Flumazenil Rescue Strategy | ||||
Brief Summary | An increase in the utilization of anesthesia and sedation medications by non-anesthesiologists, including dentists, has grown dramatically. This has been prompted, in part, by the need for pharmacological tools to address high levels of fear and anxiety about dental care among the US population and the evidence of oral health disparities among those who are fearful . Given the prevalence of dental fear in the general population and in the various populations with the greatest burden of oral diseases, effective sedation techniques are needed that are safe and effective in the hands of general dentists that make up the "front line" in the efforts to reduce oral health disparities. This study is to determine whether, when compared to a saline placebo, a single intraoral submucosal administration of the benzodiazepine antagonist flumazenil (0.2 mg) is capable of attenuating in 10 minutes or less the central nervous system (CNS) depression produced by a paradigm of stacked sublingual dosing of triazolam (3 doses of 0.25 mg over 90 minutes). |
||||
Detailed Description | |||||
Study Type ICMJE | Interventional | ||||
Study Phase | Phase 1 Phase 2 |
||||
Study Design ICMJE | Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
||||
Condition ICMJE | Dental Anxiety | ||||
Intervention ICMJE |
|
||||
Study Arm (s) |
|
||||
Publications * | Jackson DL, Milgrom P, Heacox GA, Kharasch ED. Pharmacokinetics and clinical effects of multidose sublingual triazolam in healthy volunteers. J Clin Psychopharmacol. 2006 Feb;26(1):4-8. | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Completed | ||||
Enrollment ICMJE | 14 | ||||
Completion Date | December 2007 | ||||
Primary Completion Date | December 2007 (final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Gender | Both | ||||
Ages | 18 Years to 40 Years | ||||
Accepts Healthy Volunteers | Yes | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Location Countries ICMJE | United States | ||||
Administrative Information | |||||
NCT Number ICMJE | NCT00695630 | ||||
Other Study ID Numbers ICMJE | 30779, U54DE14254, T32007132 | ||||
Has Data Monitoring Committee | No | ||||
Responsible Party | Peter Milgrom/Professor of Dental Public Health Sciences, University of Washington | ||||
Study Sponsor ICMJE | University of Washington | ||||
Collaborators ICMJE | National Institutes of Health (NIH) | ||||
Investigators ICMJE |
|
||||
Information Provided By | University of Washington | ||||
Verification Date | June 2008 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |